{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:52:35Z","timestamp":1777686755751,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:p>Huntington\u2019s disease (HD) is a devastating neurodegenerative disorder that urgently needs disease-modifying therapeutics. To this end, collaboration to standardize clinical research practices in the field and drive progress in addressing drug development challenges is paramount. At a meeting in 2017 organized by CHDI Foundation and the Critical Path Institute, stakeholders across the pharmaceutical industry, academia, regulatory agencies, and patient advocacy groups discussed the need for and potential impact of a consortium dedicated to HD regulatory science. Consequently, the Huntington\u2019s Disease Regulatory Science Consortium (HD-RSC) was formed, a precompetitive consortium that is dedicated to building a regulatory strategy to expedite the approval of HD therapeutics.<\/jats:p>","DOI":"10.3233\/jhd-220533","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:29:37Z","timestamp":1650626977000},"page":"97-104","source":"Crossref","is-referenced-by-count":3,"title":["Huntington\u2019s Disease Regulatory Science Consortium: Accelerating Medical Product Development"],"prefix":"10.1177","volume":"11","author":[{"given":"Emily C.","family":"Turner","sequence":"first","affiliation":[{"name":"Critical Path Institute, Tucson, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C.","family":"Gantman","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[{"name":"CHDI Management\/CHDI Foundation, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Sivakumaran","sequence":"additional","affiliation":[{"name":"Critical Path Institute, Tucson, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/JHD-220533_ref1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group","volume":"72","author":"Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"issue":"3","key":"10.3233\/JHD-220533_ref2","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.3233\/JHD-220533_ref3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-220533_ref4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cpt.42","article-title":"Catalyzing the Critical Path Initiative: FDA\u2019s progress in drug development activities","volume":"97","author":"Parekh","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.3233\/JHD-220533_ref9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/cts.12845","article-title":"Standardized data structures in rare diseases: CDISC user guides for Duchenne muscular dystrophy and Huntington\u2019s disease","volume":"14","author":"Mullin","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.3233\/JHD-220533_ref10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jalz.2016.04.001","article-title":"Collaboration for Alzheimer\u2019s Prevention: Principles to guide data and sample sharing in preclinical Alzheimer\u2019s disease trials","volume":"12","author":"Weninger","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.3233\/JHD-220533_ref11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.16","article-title":"The future is now: model-based clinical trial design for Alzheimer\u2019s disease","volume":"97","author":"Romero","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.3233\/JHD-220533_ref12","doi-asserted-by":"crossref","first-page":"712555","DOI":"10.3389\/fneur.2021.712555","article-title":"Volumetric MRI-based biomarkers in Huntington\u2019s disease: an evidentiary review","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurol"},{"key":"10.3233\/JHD-220533_ref13","doi-asserted-by":"crossref","first-page":"712565","DOI":"10.3389\/fneur.2021.712565","article-title":"Recommendations to optimize the use of volumetric MRI in Huntington\u2019s disease clinical trials","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front Neurol"},{"issue":"11","key":"10.3233\/JHD-220533_ref14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/1352458517723718","article-title":"The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability","volume":"24","author":"LaRocca","year":"2018","journal-title":"Mult Scler"},{"issue":"2","key":"10.3233\/JHD-220533_ref15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.3233\/JHD-220533_ref16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/ene.13889","article-title":"Longitudinal assessment of the Unified Huntington\u2019s Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington\u2019s disease","volume":"26","author":"Winder","year":"2019","journal-title":"Eur J Neurol"},{"issue":"12","key":"10.3233\/JHD-220533_ref17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/mds.25654","article-title":"Unified Huntington\u2019s disease rating scale for advanced patients: validation and follow-up study","volume":"28","author":"Youssov","year":"2013","journal-title":"Mov Disord"},{"issue":"10","key":"10.3233\/JHD-220533_ref19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/mds.25964","article-title":"HD-CAB: A cognitive assessment battery for clinical trials in Huntington\u2019s disease","volume":"29","author":"Stout","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-220533_ref20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40900-018-0093-3","article-title":"Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation","volume":"4","author":"Chalasani","year":"2018","journal-title":"Res Involv Engagem"},{"issue":"5","key":"10.3233\/JHD-220533_ref21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mds.27671","article-title":"A roadmap for implementation ofpatient-centered digital outcome measures in Parkinson\u2019s diseaseobtained using mobile health technologies","volume":"34","author":"Espay","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-220533_ref22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/eb-2018-102890","article-title":"Digital technologies for the assessment of cognition: a clinical review","volume":"21","author":"Chinner","year":"2018","journal-title":"Evid Based Ment Health"},{"issue":"9","key":"10.3233\/JHD-220533_ref23","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.26642","article-title":"Technology in Parkinson\u2019s disease: Challenges and opportunities","volume":"31","author":"Espay","year":"2016","journal-title":"Mov Disord"},{"issue":"4","key":"10.3233\/JHD-220533_ref25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-220533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:07Z","timestamp":1777452967000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-220533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":19,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jhd-220533","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]}}}